Last reviewed · How we verify

TachoSil® patches — Competitive Intelligence Brief

TachoSil® patches (TachoSil® patches) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agent. Area: Surgery.

phase 3 Hemostatic agent Surgery Small molecule Live · refreshed every 30 min

Target snapshot

TachoSil® patches (TachoSil® patches) — Swiss Cancer Institute. TachoSil patches work by promoting hemostasis and tissue sealing through the release of fibrinogen and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TachoSil® patches TARGET TachoSil® patches Swiss Cancer Institute phase 3 Hemostatic agent
Fibrinogen + PCC Fibrinogen + PCC University Health Network, Toronto marketed Hemostatic agent / Coagulation factor replacement
Blood Stopper (Ankaferd) Blood Stopper (Ankaferd) Ankara Ataturk Sanatorium Training and Research Hospital marketed Topical hemostatic agent
rFVIIa, rFVIIa + TXA rFVIIa, rFVIIa + TXA Oslo University Hospital marketed Hemostatic agents Extrinsic coagulation pathway and fibrinolysis inhibition
Fibrinogen/thrombin-coated collagen patch Fibrinogen/thrombin-coated collagen patch Asan Medical Center marketed Hemostatic agent / Surgical sealant
Hemoblast Bellows application Hemoblast Bellows application WakeMed Health and Hospitals marketed Hemostatic agent
Patients receive microporous polysaccharide hemospheres. Patients receive microporous polysaccharide hemospheres. Fundación para la Investigación del Hospital Clínico de Valencia marketed Topical hemostatic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemostatic agent class)

  1. Chang Gung Memorial Hospital · 1 drug in this class
  2. DeNova Research · 1 drug in this class
  3. Ethicon, Inc. · 1 drug in this class
  4. Mallinckrodt · 1 drug in this class
  5. Sun Yat-sen University · 1 drug in this class
  6. Swiss Cancer Institute · 1 drug in this class
  7. Takeda · 1 drug in this class
  8. WakeMed Health and Hospitals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TachoSil® patches — Competitive Intelligence Brief. https://druglandscape.com/ci/tachosil-patches. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: